Telo Genomics Corp.
TDSGF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.03M
Close$
$0.00
86.9% downside
Current Fair Value
86.9% downsideOvervalued by 86.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.03 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.02 |
| Beta | 0.24 |
| Outstanding Shares | 100,430,472 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3 |
|---|---|
| PEG | 8.92 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 25, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Telo Genomics Corp.
8 employees
CEO: John Allen Farlinger
Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenge...